• Categories:Qijian News
• Author:
• Origin:
• Time of issue:2024-11-14
• Views:0

(Summary description)Jilin Qijian’s butylphthalide API was successfully approved for market listing on 12th Nov 2024. this marks a significant progress of our drug research and development. This achievement not only lays a solid foundation for the clinical application of butylphthalide injection, but also opens up a broad prospect for our company in R&D and production in the future.



The successful application for the registration number of butylphthalide API is the result of our company's long-term investment and unremitting efforts in the field of drug research and development. On the basis of in-depth research on the pharmacological mechanism of butylphthalide, our R&D team has continuously optimized the production process and quality control standards to ensure the safety and efficacy of the product. At the same time, we also actively communicated and collaborated with China FDA and other relevant departments, declared in strict accordance with the relevant regulations and guidelines, and ultimately obtained this important achievement.



In the future, we will continue to increase investment in research and development, deepen cooperation with domestic and foreign research institutions and medical institutions, and promote the research and development and application of innovative medicines, so as to bring benefits to more patients. We will continue to uphold the corporate spirit of ‘Integrity, Innovation and Responsibility’ and commit ourselves to provide patients around the world with safer, more effective and more convenient medicines and services. At the same time, we will also actively fulfil our social responsibility and promote the healthy and sustainable development of the pharmaceutical industry.